Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: July 24, 2017
What is the patent landscape for Ibandronate Sodium, and what generic Ibandronate Sodium alternatives are available?
Ibandronate Sodium is a drug marketed by Aurobindo Pharma Ltd, Watson Labs Teva, Apotex Inc, Sagent Pharms, Sun Pharm Inds Ltd, Accord Hlthcare, Mylan Labs Ltd, Emcure Pharms Ltd, Mylan Pharms Inc, Sun Pharm Inds, Dr Reddys Labs Ltd, and Orchid Hlthcare. and is included in fourteen NDAs.| Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 14 |
| Suppliers / Packagers: see list | 12 |
| Bulk Api Vendors: see list | 129 |
| Clinical Trials: see list | 2,427 |
| Patent Applications: see list | 5,791 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | IBANDRONATE SODIUM at DailyMed |
| Ingredient-type | Diphosphonates |
| Drug Class | Bisphosphonate |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Ltd | IBANDRONATE SODIUM | ibandronate sodium | TABLET;ORAL | 204502-001 | Mar 11, 2016 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Sun Pharm Inds Ltd | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 090853-001 | Feb 14, 2014 | AP | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Aurobindo Pharma Ltd | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 205332-001 | Aug 19, 2015 | AP | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Sun Pharm Inds | IBANDRONATE SODIUM | ibandronate sodium | TABLET;ORAL | 078996-001 | Aug 15, 2012 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Accord Hlthcare | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 206058-001 | Feb 5, 2016 | AP | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,105 others who get our Drug Patent Expiration Alerts:
